Uruguayan Government Grants Plandai Biotechnology Provisional License for the Research & Development of Prescription Cannabinoid Medicines

LOGAN, UT--(Marketwired - May 14, 2015) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), announced today that the Government of Uruguay, through its Institute of Regulation and Control of Cannabis (IRCCA), granted Plandai Biotechnology Uruguay S.A. a provisional license under the Marijuana and Derivates Law 19.172, Decree No.46/2015, Articles 6 and 9, to establish a scientific program for the research, and development of prescription cannabinoid medicines.

The Company’s legal counsel, Ferrere Abogados of Montevideo, Uruguay, represented the Company throughout the licensing process. The Company’s license is provisional and subject to the Company submitting additional information to the IRCCA within 90 days in order to finalize issuance of the license. The Company, in conjunction with its counsel, expects to submit all required paperwork to the IRCCA in a timely fashion and will update shareholders on its progress.

Once issued, the Company’s license will allow it to undertake in vitro and murine investigations, extending to human studies once the initial research has been completed.

Previously, Uruguay’s Ministry of Health granted the Company permission to grow, harvest and process live cannabis for the formulation of Phytofare™ cannabinoid complexes on September 16, 2014.

Dr. Mercedes Gonzalez, a Professor of Organic Chemistry, and the Director of the Research Group of Medicinal Chemistry, Faculty of Science, University of the Republic, Uruguay, will be the Scientific Director of the Plandaí Cannabis Research Project. The Project parameters are defined in an agreement between Plandai Uruguay, the Foundation for the Development of Basic Sciences, and the University’s Group of Medicinal Chemistry, and it includes ownership by Plandai USA of all new scientific discoveries and intellectual property resulting from the Project.

The project will be undertaken in a new, secure and dedicated scientific building that will be constructed at the Technological Laboratory of Uruguay (LATU) Research Park, Montevideo, which will support a team of scientists, technicians and agronomists specializing in cannabis research and husbandry.

Ms. Victoria Vergara, Esq. of Ferrere Abogados of Montevideo, Uruguay, commented: “We are proud to have been involved in representing Plandai Uruguay during this process and we expect to be able to supply all of the necessary information within the 90 day window.”

The Project will focus solely on non-psychoactive cannabis drug chemistry containing a complex of cannabinoids, cannabinoid acids and other phytonutrients. Product profiling will include bioavailability and dosage; as well as safety and efficacy.

The medicinal studies will be initially investigated through in vitro and mouse modeling and will focus primarily with the brain signaling system to establish benefits and/or improvements to a variety of physiological processes including appetite, pain-sensation, mood, and memory.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. The company controls every aspect of the process, from growing the current green tea on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical.

For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.